Tag: aromataseInhibitors

Articles

• Aromatase inhibitor treatment and weight gain
• BC patients who gain weight after diagnosis have worse prognosis
• Foods that act as aromatase inhibitors
• Foods to eat & avoid during aromatase inhibitor treatment
• Fruit and aromatase inhibitors for breast cancer
• Herbs & spices and aromatase inhibitors for breast cancer
• Impact of endocrine therapy (hormone therapy) on BC prognosis
• Vegetables and aromatase inhibitors for breast cancer

News

08/26/17

Walking can reduce aromatase inhibitor-induced joint pain

01/12/15

Early birth control pill use linked to premenopausal BC recurrence

07/19/12

Aromatase inhibitors are less effective in women with high BMI

03/08/12

Heart drug digoxin (digitalis) increases risk of breast cancer

02/06/12

Soy supplements do not reduce breast cancer risk and could be harmful

10/19/11

Tumor response to anti-estrogen treatment before surgery varies

07/17/11

Increasing aromatase inhibitor side effects make tamoxifen attractive

06/09/11

Patients with ER-/PR+ breast cancer benefit from endocrine therapy

Studies

• Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial Cite
  Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, et al. Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial. International Journal of Cancer. Wiley; 2025; 10.1002/ijc.70037
• The Cytochrome CYP4 in Breast and Other Cancers Cite
  Calaf GM, Crispin LA, Ossandon-Acosta F, Perez-Tapia S, Ardiles LN. The Cytochrome CYP4 in Breast and Other Cancers. Biology. MDPI AG; 2025; 14:812 10.3390/biology14070812
• Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer Cite
  Lund M, Corn G, Jensen M, Petersen T, Dalhoff K, Ejlertsen B, et al. Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer. European Journal of Epidemiology. Springer Science and Business Media LLC; 2025; 10.1007/s10654-025-01228-7
• Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer Cite
  Beck AS, Earley M, Troxell M, Tsai J, Telli ML, Wapnir IL. Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2025; 10.1007/s10549-025-07722-6
• Differential Effects of Endocrine Therapy Type on Quality of Life in Older (≥70 Years) Women with Early-Stage Breast Cancer Cite
  Li K, Moshier E, Shao T, Rosenstein BS, Chadha M. Differential Effects of Endocrine Therapy Type on Quality of Life in Older (≥70 Years) Women with Early-Stage Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2025; 10.1245/s10434-024-16482-4
• Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer Cite
  Choong GM, Hoskin TL, Boughey JC, Ingle JN, Goetz MP. Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2025; 10.1200/jco-24-02263
• Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk Cite
  Sarkar S, Schechter C, Kurian AW, Caswell-Jin JL, Jayasekera J, Mandelblatt JS. Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk. npj Breast Cancer. Springer Science and Business Media LLC; 2025; 11 10.1038/s41523-025-00746-7
• Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors Cite
  Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, et al. Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2025; 10.1093/jnci/djaf063
• Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study Cite
  Dumas E, Jochum F, Coussy F, Hamy A, Majdling A, Houzard S, et al. Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2025; 10.1200/jco.24.01131
• Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBas) Cite
  Yuste MT, Sainz‐Gil M, Escudero E, Marín P. Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBas). Pharmacology Research & Perspectives. Wiley; 2025; 13 10.1002/prp2.70075
• Current Evidence on the Impact of Diet, Food, and Supplement Intake on Breast Cancer Health Outcomes in Patients Undergoing Endocrine Therapy Cite
  Žuža Praštalo M, Pokimica B, Arsić A, Ilich JZ, Vučić V. Current Evidence on the Impact of Diet, Food, and Supplement Intake on Breast Cancer Health Outcomes in Patients Undergoing Endocrine Therapy. Nutrients. MDPI AG; 2025; 17:456 10.3390/nu17030456
• Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion Cite
  Kastora SL, Pantiora E, Hong YH, Veeramani M, Azim HA, Chakrabarti R, et al. Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion. Cancer Treatment Reviews. Elsevier BV; 2025; 133:102880 10.1016/j.ctrv.2025.102880
• Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study Cite
  Mostofsky E, Buring JE, Come SE, Tung NM, Zhang C, Mukamal KJ. Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study. Breast Cancer Research. Springer Science and Business Media LLC; 2025; 27 10.1186/s13058-024-01940-4
• Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial Cite
  Faltinová M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, Virtanen A, Haanpää M, et al. Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07564-8
• Clinical and histomorphometric evaluation of the vagina following treatment with CO2 laser, radiofrequency, and promestriene for genitourinary syndrome of menopause in breast cancer survivors on adjuvant therapy Cite
  Cantarelli GC, Bianchi-Ferraro AM, Dedonatto C, Fernandes MF, Vanzin RB, Dardes RC, et al. Clinical and histomorphometric evaluation of the vagina following treatment with CO2 laser, radiofrequency, and promestriene for genitourinary syndrome of menopause in breast cancer survivors on adjuvant therapy. Maturitas. Elsevier BV; 2025; 191:108155 10.1016/j.maturitas.2024.108155
• Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018 Cite
  Bowles EJA, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, et al. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 208:577-587 10.1007/s10549-024-07453-0
• Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy Cite
  Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, et al. Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07509-1
• Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: does dietary counseling matter? Cite
  Pedersini R, Schivardi G, Laganà M, Laini L, di Mauro P, Zamparini M, et al. Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: does dietary counseling matter?. The Breast. Elsevier BV; 2024;:103794 10.1016/j.breast.2024.103794
• Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors Cite
  Fansa S, Ghusn W, Tama E, Nicolalde B, Anazco D, Andre SD, et al. Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07450-3
• Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer Cite
  Cai C, Strickland K, Knudsen S, Tucker SB, Chidrala CS, Modugno F. Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2024; 7:e2422493 10.1001/jamanetworkopen.2024.22493
• Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials Cite
  Lu W, Giobbie‐Hurder A, Tanasijevic A, Kassis SB, Park SH, Jeong YJ, et al. Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials. Cancer. Wiley; 2024; 10.1002/cncr.35374
• Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors Cite
  Chang C, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, et al. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 130:1943-1950 10.1038/s41416-024-02680-0
• A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors Cite
  Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, et al. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:4548-4561 10.1200/jco.23.00697
• 268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation Cite
  Dumas E, Hamy-Petit A, Gougis P, Laas E, El Ferjaoui S, Jochum F, et al. 268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation. ESMO Open. Elsevier BV; 2024; 9:103327 10.1016/j.esmoop.2024.103327
• Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial Cite
  Giacchetti S, Laas E, Bachelot T, Lemonnier J, André F, Cameron D, et al. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial. eBioMedicine. Elsevier BV; 2024; 104:105141 10.1016/j.ebiom.2024.105141
• Effect of obesity and endocrine therapy on the prognosis of premenopausal women with HR+HER2-breast cancer: a multi-center retrospective study Cite
  Lian W, Hong C, Wang C, Chen D. Effect of obesity and endocrine therapy on the prognosis of premenopausal women with HR+HER2-breast cancer: a multi-center retrospective study. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4315013/v1
• Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study Cite
  Blomqvist C, Vehmanen L, Kellokumpu-Lehtinen P, Huovinen R, Ruohola J, Penttinen H, et al. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07252-7
• Evaluating flavonoids as potential aromatase inhibitors for breast cancer treatment: In vitro studies and in silico predictions Cite
  Seo JI, Yu JS, Zhang Y, Yoo HH. Evaluating flavonoids as potential aromatase inhibitors for breast cancer treatment: In vitro studies and in silico predictions. Chemico-Biological Interactions. Elsevier BV; 2024;:110927 10.1016/j.cbi.2024.110927
• Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial Cite
  Bender CM, Sereika SM, Gentry AL, Cuglewski C, Duquette J, Grove G, et al. Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial. Psycho-Oncology. Wiley; 2024; 33 10.1002/pon.6298
• Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery? Cite
  van de Loo ME, Andour L, van Heesewijk AE, Oosterkamp HM, Liefers G, Straver ME. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-023-07222-5
• Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial Cite
  Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. The Lancet Oncology. Elsevier BV; 2023; 10.1016/s1470-2045(23)00578-8
• The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation Cite
  Gomaa S, Lopez A, Slamon R, Smith R, Lapitan E, Nightingale G, et al. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation. Supportive Care in Cancer. Springer Science and Business Media LLC; 2023; 31 10.1007/s00520-023-08170-y
• Search for New Inhibitors of Human Aromatase Enzyme (Cyp450) from Bioactive Compounds of Citrus species Cite
  Saha M, Chatterjee S. Search for New Inhibitors of Human Aromatase Enzyme (Cyp450) from Bioactive Compounds of Citrus species. Oriental Journal Of Chemistry. Oriental Scientific Publishing Company; 2023; 39:1239-1251 10.13005/ojc/390517
• Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy Cite
  Thomas NS, Scalzo RL, Wellberg EA. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nature Reviews Endocrinology. Springer Science and Business Media LLC; 2023; 10.1038/s41574-023-00899-0
• Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis Cite
  He P, Li J, Chen M, Huang M, Qiu Y, Cai Q, et al. Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07105-9
• Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer Cite
  Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K, et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 202:473-483 10.1007/s10549-023-07097-6
• Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events Cite
  Mitchell JM, DeLeire T, Isaacs C. Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events. Cancer. Wiley; 2023; 10.1002/cncr.35009
• 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis Cite
  Petrelli F, Cavallone M, Dottorini L. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis. European Journal of Cancer. Elsevier BV; 2023;:113322 10.1016/j.ejca.2023.113322
• Curcumin for Aromatase Inhibitor-Induced Joint Pain in Breast Cancer Survivors - The CurPain Trial: A Randomized, Double-Blind, Phase III, Multicenter Clinical Trial Cite
  Apostolou M, Mery T, Aivasovsky I, Akamatsu M, Daibes M, Araujo W, et al. Curcumin for Aromatase Inhibitor-Induced Joint Pain in Breast Cancer Survivors - The CurPain Trial: A Randomized, Double-Blind, Phase III, Multicenter Clinical Trial. Principles and Practice of Clinical Research Journal. Principles and Practice of Clinical Research; 2023; 9 10.21801/ppcrj.2023.92.10
• The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy Cite
  Oner G, Broeckx G, Van Berckelaer C, Zwaenepoel K, Altintas S, Canturk Z, et al. The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy. Cancer Medicine. Wiley; 2023; 10.1002/cam4.6425
• Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole. Cite
  Abdel Gelil M. Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2023; 9:8-8 10.1200/go.2023.9.supplement_1.8
• Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement Cite
  Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07054-3
• AROMATASE INHIBITION ACTIVITY OF CITRUS FRUITS AGAINST BREAST CANCER Cite
  Naveen F, Sri H, Kannayiram G. AROMATASE INHIBITION ACTIVITY OF CITRUS FRUITS AGAINST BREAST CANCER. International Research Journal of Modernization in Engineering Technology & Science. International Research Journal of Modernization in Engineering Technology and Science; 2023; 10.56726/irjmets43079
• Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation Cite
  Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, et al. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad109
• In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment Cite
  Bezerra PHA, Amaral C, Almeida CF, Correia-da-Silva G, Torqueti MR, Teixeira N. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules. MDPI AG; 2023; 28:4893 10.3390/molecules28134893
• Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review Cite
  Eliassen FM, Blåfjelldal V, Helland T, Hjorth CF, Hølland K, Lode L, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11122-8
• Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis Cite
  Park H, Park M, Kim K, Kang T. Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis. Journal of Breast Disease. Korean Breast Cancer Society; 2023; 11:1-10 10.14449/jbd.2023.11.1.1
• Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial. Cite
  Giacchetti S, Laas E, Bachelot T, Lemonnier J, Andre F, Cameron DA, et al. Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:546-546 10.1200/jco.2023.41.16_suppl.546
• 94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis Cite
  Lammers S, Geurts S, van Hellemond I, Swinkels A, Smorenburg C, van der Sangen M, et al. 94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis. ESMO Open. Elsevier BV; 2023; 8:101318 10.1016/j.esmoop.2023.101318
• Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy? Cite
  Karaboyun K, Cavdar E, Irıagac Y, Celebı A, Kapagan T, Gulturk I, et al. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?. Supportive Care in Cancer. Springer Science and Business Media LLC; 2023; 31 10.1007/s00520-023-07791-7
• Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Cite
  Sella T, Zheng Y, Rosenberg SM, Ruddy KJ, Gelber SI, Tamimi RM, et al. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00529-y
• Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial Cite
  Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, et al. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.22.00577
• Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial Cite
  Zhang X, Gunda A, Kranenbarg EM, Liefers G, Savitha BA, Shrivastava P, et al. Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01643-2
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) Cite
  Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01626-3
• Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy Cite
  Shia W, Lin L, Wu H, Chen C, Chen D. Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy. Cancer Control. SAGE Publications; 2023; 30:107327482311609 10.1177/10732748231160991
• Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method. Cite
  Van Houdt M, Han S, Pauwels S, Billen J, Neven P. Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.. Clinical Breast Cancer. Elsevier BV; 2023; 23:84-90 10.1016/j.clbc.2022.09.007
• Association between Endocrine Therapy and Cognitive Decline in Older Women with Early Breast Cancer: Findings from the Prospective CLIMB Study Cite
  Baltussen JC, Derks MG, Lemij AA, de Glas NA, Fiocco M, Linthorst-Niers EM, et al. Association between Endocrine Therapy and Cognitive Decline in Older Women with Early Breast Cancer: Findings from the Prospective CLIMB Study. European Journal of Cancer. Elsevier BV; 2023; 10.1016/j.ejca.2023.02.008
• Prolonged endocrine therapy in the management of hormone receptor‐positive early‐stage breast cancer: What is the appropriate duration? Cite
  Micha JP, Rettenmaier MA, Bohart RD, Goldstein BH. Prolonged endocrine therapy in the management of hormone receptor‐positive early‐stage breast cancer: What is the appropriate duration?. Journal of Obstetrics and Gynaecology Research. Wiley; 2023; 10.1111/jog.15553
• The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model Cite
  Boszkiewicz K, Moreira H, Sawicka E, Szyjka A, Piwowar A. The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model. Cancers. MDPI AG; 2023; 15:457 10.3390/cancers15020457
• Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study Cite
  Houvenaeghel G, de Nonneville A, Cohen M, Classe J, Reyal F, Mazouni C, et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer. Elsevier BV; 2022; 176:58-69 10.1016/j.ejca.2022.08.027
• Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers Cite
  Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, et al. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06688-z
• Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance? Cite
  Cathcart-Rake EJ, Ruddy KJ. Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 10.1093/jnci/djac113
• Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis Cite
  Zeng E, He W, Smedby KE, Czene K. Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2022; 20:683-689.e2 10.6004/jnccn.2021.7116
• Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer. Cite
  Robien K, Kirstein MN, Pawloski PA, Shapiro AC. Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:e12535-e12535 10.1200/jco.2022.40.16_suppl.e12535
• Weight Gain after Hormone Receptor-Positive Breast Cancer Cite
  Goyal A, Milner GE, Cimino-Mathews A, Visvanathan K, Wolff AC, Sharma D, et al. Weight Gain after Hormone Receptor-Positive Breast Cancer. Current Oncology. MDPI AG; 2022; 29:4090-4103 10.3390/curroncol29060326
• Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors Cite
  Nijhof AVO-, Jacobse JN, Steggink LC, Lefrandt JD, Gietema JA, Leeuwen FEV, et al. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1626546/v1
• Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy Cite
  Matar R, Sevilimedu V, Gemignani ML, Morrow M. Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-11728-5
• Does the toxicity of endocrine therapy persist into long-term survivorship? – Patient-reported outcome results from a follow-up study beyond a 10-year-survival Cite
  Albertini C, Oberguggenberger A, Sztankay M, Egle D, Giesinger J, Meraner V, et al. Does the toxicity of endocrine therapy persist into long-term survivorship? – Patient-reported outcome results from a follow-up study beyond a 10-year-survival. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1526913/v1
• Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model Cite
  Hilakivi-Clarke L, Da Silva JL, Blaes A, Hoeppner L. Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P5-18-12-P5-18-12 10.1158/1538-7445.sabcs21-p5-18-12
• Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status Cite
  Hills RK, Oesterreich S, Metzger O, Dabbs D, Pan H, Braybrooke J, et al. Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:PD14-08-PD14-08 10.1158/1538-7445.sabcs21-pd14-08
• No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach Cite
  Clèries R, Buxó M, Vilardell M, Ameijide A, Martínez JM, Font R, et al. No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach. International Journal of Environmental Research and Public Health. MDPI AG; 2022; 19:3605 10.3390/ijerph19063605
• Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study Cite
  Moskalewicz A, Di Tomaso A, Kachura JJ, Scime S, Nisenbaum R, Lee R, et al. Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study. Current Oncology. MDPI AG; 2022; 29:1813-1827 10.3390/curroncol29030149
• De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort Cite
  Cai Y, Shao Z, Yu K. De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort. Cancer. Wiley; 2022; 10.1002/cncr.34155
• Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy Cite
  Fu F, Yu L, Zeng B, Chen M, Guo W, Chen L, et al. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2145934 10.1001/jamanetworkopen.2021.45934
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
• Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go??? Cite
  Jacobs CF, Soesan M, Sonke GS. Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06505-z
• Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation Cite
  Heo JH, Lee SR, Jo SL, Yang H, Lee HW, Hong E. Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation. International Journal of Molecular Sciences. MDPI AG; 2022; 23:547 10.3390/ijms23010547
• Evaluation of Adjuvant Radiation and Endocrine Therapy in Elderly Patients with Early-Stage Breast Cancer Cite
  Ma S, Yu B, Oladeru O, Bartl A, Farrugia M, Fekrmandi F, et al. Evaluation of Adjuvant Radiation and Endocrine Therapy in Elderly Patients with Early-Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e207-e208 10.1016/j.ijrobp.2021.07.734
• Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer Cite
  Fahey M, Mills M, Liveringhouse C, Ronica N, Diaz R. Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e206 10.1016/j.ijrobp.2021.07.730
• Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions Cite
  Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
• Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions Cite
  Sella T, Ruddy KJ, Carey LA, Partridge AH. Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice. American Society of Clinical Oncology (ASCO); 2021; 10.1200/op.21.00482
• Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy Cite
  Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology. Elsevier BV; 2021; 32:1256-1266 10.1016/j.annonc.2021.07.017
• Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years Cite
  Riyad AY, Elkhodary DA, Elghamry WRF, Zaki IAKM. Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years. QJM: An International Journal of Medicine. Oxford University Press (OUP); 2021; 114 10.1093/qjmed/hcab103.010
• Design, Synthesis and Biological Evaluation of Aromatase Inhibitors based on Sulfonates and Sulfonamides of Resveratrol Cite
  Fantacuzzi M, Gallorini M, Gambacorta N, Ammazzalorso A, Aturki Z, Balaha M, et al. Design, Synthesis and Biological Evaluation of Aromatase Inhibitors based on Sulfonates and Sulfonamides of Resveratrol. Pharmaceuticals. MDPI AG; 2021; 14:984 10.3390/ph14100984
• Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival Cite
  Taroeno-Hariadi KW, Putra YR, Choridah L, Widodo I, Hardianti MS, Aryandono T. Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival. Journal of Breast Cancer. Korean Breast Cancer Society; 2021; 24 10.4048/jbc.2021.24.e41
• Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial Cite
  Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2021; 10.1016/s1470-2045(21)00352-1
• Role of estrogen receptor coregulators in endocrine resistant breast cancer Cite
  Altwegg KA, Vadlamudi RK. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy. Open Exploration Publishing; 2021;:385-400 10.37349/etat.2021.00052
• Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice Cite
  Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice. Endocrinology. The Endocrine Society; 2021; 10.1210/endocr/bqab174
• Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes Cite
  Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A, et al. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10459-3
• Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer Cite
  Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, et al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2021; 385:395-405 10.1056/nejmoa2104162
• Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial Cite
  Shenouda M, Copley R, Pacioles T, Lebowicz Y, Jamil M, Akpanudo S, et al. Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.06.007
• Association between Endocrine Therapy and Weight Gain after Breast Cancer Diagnosis among Japanese Patients: A Retrospective Cohort Study Cite
  Okumatsu K, Yamauchi H, Kotake R, Gosho M, Nakata Y. Association between Endocrine Therapy and Weight Gain after Breast Cancer Diagnosis among Japanese Patients: A Retrospective Cohort Study. Medical Sciences. MDPI AG; 2021; 9:50 10.3390/medsci9030050
• Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study Cite
  Sund M, Garcia-Argibay M, Garmo H, Ahlgren J, Wennstig A, Fredriksson I, et al. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. The Breast. Elsevier BV; 2021; 59:157-164 10.1016/j.breast.2021.07.004
• Vaginal Laser Therapy for Genitourinary Syndrome of Menopause – Systematic Review Cite
  Mension E, Alonso I, Tortajada M, Matas I, Gómez S, Ribera L, et al. Vaginal Laser Therapy for Genitourinary Syndrome of Menopause – Systematic Review. Maturitas. Elsevier BV; 2021; 10.1016/j.maturitas.2021.06.005
• Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study Cite
  Mamguem Kamga A, Billa O, Ladoire S, Poillot M, Jolimoy G, Roignot P, et al. Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study. The Breast. Elsevier BV; 2021; 10.1016/j.breast.2021.06.003
• Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients Cite
  Dackus GM, Jóźwiak K, Sonke GS, van der Wall E, van Diest PJ, Siesling S, et al. Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab091
• Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer Cite
  Showalter SL, Meneveau MO, Keim-Malpass J, Camacho TF, Squeo G, Anderson RT. Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10064-4
• Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States Cite
  Faiz AS, Guo S, Kaveney A, Philipp CS. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States. Blood Coagulation & Fibrinolysis. Ovid Technologies (Wolters Kluwer Health); 2021; Publish Ahead of Print 10.1097/mbc.0000000000001043
• Association of Endocrine Therapy and Dementia in Women with Breast Cancer Cite
  Thompson MR, Niu J, Lei X, Nowakowska M, Wehner MR, Giordano SH, et al. Association of Endocrine Therapy and Dementia in Women with Breast Cancer. Breast Cancer: Targets and Therapy. Informa UK Limited; 2021; Volume 13:219-224 10.2147/bctt.s300455
• Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data Cite
  Lailler G, Memoli V, Le Bihan Benjamin C, Ben Diane M, Lauzier S, Mancini J, et al. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.01.007
• Fractional CO₂ vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors Cite
  Siliquini GP, Bounous VE, Novara L, Giorgi M, Bert F, Biglia N. Fractional CO₂ vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors. The Breast Journal. Wiley; 2021; 10.1111/tbj.14211
• Distribution of dyslipidemia in Chinese early breast cancer patients at diagnosis and comparison of dyslipidemia incidence following different endocrine therapies: a population-based cohort study Cite
  Wang J, Yin J, Qiu J, Jiang J, Hu Y, Zheng H, et al. Distribution of dyslipidemia in Chinese early breast cancer patients at diagnosis and comparison of dyslipidemia incidence following different endocrine therapies: a population-based cohort study. Research Square; 2021; 10.21203/rs.3.rs-298866/v1
• Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial Cite
  Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06168-w
• Weight Changes According to Treatment in a Diverse Cohort of Breast Cancer Patients Cite
  Fukui J, White K, Frankland T, Oshiro C, Wilkens L. Weight Changes According to Treatment in a Diverse Cohort of Breast Cancer Patients. Research Square; 2021; 10.21203/rs.3.rs-260561/v1
• From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors Cite
  Vasconcelos de Matos L, Fernandes L, Neves MT, Alves F, Baleiras M, Ferreira A, et al. From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors. Current Oncology. MDPI AG; 2021; 28:1067-1076 10.3390/curroncol28020104
• Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ Cite
  Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, et al. Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. General Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-gs2-02
• Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men Cite
  Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter H, et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. JAMA Oncology. American Medical Association (AMA); 2021; 10.1001/jamaoncol.2020.7442
• Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial Cite
  Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, et al. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-020-01228-2
• Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review Cite
  Shirdarreh M, Pezo RC. Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review. Breast Cancer. Springer Science and Business Media LLC; 2021; 10.1007/s12282-020-01213-w
• Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer Cite
  Robertson JF, Paridaens RJ, Lichfield J, Bradbury I, Campbell C. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer. Elsevier BV; 2021; 145:19-28 10.1016/j.ejca.2020.11.038
• The immunomodulatory effects of endocrine therapy in breast cancer Cite
  Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, et al. The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2021; 40 10.1186/s13046-020-01788-4
• Most women with breast cancer about to initiate aromatase inhibitors already have bone loss Cite
  Gil RHS, Rodríguez ER, Rodríguez LR, Delgado HR, Jurado JC, Pérez MS, et al. Most women with breast cancer about to initiate aromatase inhibitors already have bone loss. Medicina Clínica Práctica. Elsevier BV; 2020; 4:100156 10.1016/j.mcpsp.2020.100156
• Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study Cite
  Schiza A, Mauri D, Fredriksson I, Anna-Karin Wennstig , Valachis A. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-06022-5
• Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells Cite
  Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. Elsevier BV; 2020; 10.1016/j.jtumed.2020.10.017
• The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy Cite
  Dell’Acqua G, Richards A, Thornton MJ. The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy. Nutrients. MDPI AG; 2020; 12:3537 10.3390/nu12113537
• Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Cite
  Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2020; 21:1443-1454 10.1016/s1470-2045(20)30458-7
• Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women Cite
  Nayyar A, Strassle PD, Iles K, Jameison D, Jadi J, McGuire KP, et al. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4853-4860 10.1245/s10434-020-08945-1
• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Cite
  Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3987-3998 10.1200/jco.20.02514
• Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer Cite
  Lee KT, Jacobs L, Walsh EM, Stearns V, Segal JB. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:965-975 10.1007/s10549-020-05910-0
• Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance Cite
  Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance. Cold Spring Harbor Laboratory; 2020; 10.1101/2020.08.21.259440
• Association of endocrine therapy with overall survival in women with hormone receptor‐positive, HER2‐negative, node‐negative breast cancer of favorable histology Cite
  Oladeru OT, Singh AK, Ma SJ. Association of endocrine therapy with overall survival in women with hormone receptor‐positive, HER2‐negative, node‐negative breast cancer of favorable histology. The Breast Journal. Wiley; 2020; 26:2006-2010 10.1111/tbj.13995
• Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database Cite
  Nahleh ZA, Elimimian EB, Elson LC, Hobbs B, Wei W, Blake CN. Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2020; 14:117822342094569 10.1177/1178223420945694
• Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study Cite
  Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, et al. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:439-450 10.1007/s10549-020-05761-9
• Physical activity, health‐related quality of life, and adjuvant endocrine therapy–related symptoms in women with hormone receptor–positive breast cancer Cite
  Sheppard VB, Dash C, Nomura S, Sutton AL, Franco RL, Lucas A, et al. Physical activity, health‐related quality of life, and adjuvant endocrine therapy–related symptoms in women with hormone receptor–positive breast cancer. Cancer. Wiley; 2020; 126:4059-4066 10.1002/cncr.33054
• Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study Cite
  Harborg S, Heide-Jørgensen U, Ahern TP, Ewertz M, Cronin-Fenton D, Borgquist S. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:153-160 10.1007/s10549-020-05749-5
• Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases Cite
  Lambert-Côté L, Bouhnik A, Bendiane M, Bérenger C, Mondor M, Huiart L, et al. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:777-790 10.1007/s10549-020-05549-x
• Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain Cite
  Font R, Espinas JA, Barnadas A, Izquierdo A, Galceran J, Saladie F, et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:733-740 10.1007/s10549-019-05201-3
• Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada. Cite
  Blanchette PS, Lam M, Le B, Richard L, Shariff S, Pritchard KI, et al. Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:521-521 10.1200/jco.2020.38.15_suppl.521
• A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting Cite
  Sánchez‐Rovira P, Hirschberg AL, Gil‐Gil M, Bermejo‐De Las Heras B, Nieto‐Magro C. A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. The Oncologist. Wiley; 2020; 25 10.1634/theoncologist.2020-0417
• Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study Cite
  Saito T, Ono R, Kono S, Asano M, Fukuta A, Tanaka Y, et al. Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:187-193 10.1007/s10549-020-05668-5
• Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis Cite
  Yuan C, Xie Z, Bian J, Huo J, Daily K. Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:819-827 10.1007/s10549-020-05591-9
• Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α Cite
  Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, et al. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. Clinical Cancer Research. American Association for Cancer Research (AACR); 2020; 26:2986-2996 10.1158/1078-0432.ccr-19-3091
• Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia Cite
  Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, et al. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 177:427-435 10.1007/s10549-019-05319-4
• Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study Cite
  Yao S, Laurent CA, Roh JM, Lo J, Tang L, Hahn T, et al. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:187-195 10.1007/s10549-019-05518-z
• Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials Cite
  Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:275-285 10.1007/s10549-019-05464-w
• Characteristics of adverse events of endocrine therapies among older patients with breast cancer Cite
  Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, et al. Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Supportive Care in Cancer. Society for Mining, Metallurgy and Exploration Inc.; 2019; 27:3813-3822 10.1007/s00520-019-04674-8
• Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update Cite
  Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:3152-3165 10.1200/jco.19.01472
• Medication Use to Reduce Risk of Breast Cancer Cite
  Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Medication Use to Reduce Risk of Breast Cancer. JAMA. American Medical Association (AMA); 2019; 322:857 10.1001/jama.2019.11885
• Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study Cite
  Pearson A, Booker A, Tio M, Marx G. Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 178:135-140 10.1007/s10549-019-05384-9
• Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK Cite
  Bromley SE, Matthews A, Smeeth L, Stanway S, Bhaskaran K. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. Journal of Cancer Survivorship. Springer Science and Business Media LLC; 2019; 13:632-640 10.1007/s11764-019-00782-w
• Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update Cite
  Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Oncology Practice. American Society of Clinical Oncology (ASCO); 2019; 15:106-107 10.1200/jop.18.00617
• Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population. Cite
  Johnson A, Agbisit C, Robinson K, Delfino K, Desai MR. Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e12048-e12048 10.1200/jco.2019.37.15_suppl.e12048
• Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors Cite
  Gibb FW, Dixon JM, Clarke C, Homer NZ, Faqehi AMM, Andrew R, et al. Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society; 2019; 104:3670-3678 10.1210/jc.2018-02339
• Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors Cite
  Baglia ML, Lin I, Cartmel B, Sanft T, Ligibel J, Hershman DL, et al. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. Wiley; 2019; 125:2262-2271 10.1002/cncr.32051
• Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial Cite
  Yu K, Wu S, Liu G, Wu J, Di G, Hu Z, et al. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer. Wiley; 2019; 10.1002/cncr.32057
• Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors Cite
  Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 174:785-794 10.1007/s10549-018-05086-8
• Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial Cite
  Mamounas EP, Bandos H, Lembersky BC, Jeong J, Geyer CE, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. Elsevier BV; 2019; 20:88-99 10.1016/s1470-2045(18)30621-1
• Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments Cite
  Ginzac A, Thivat É, Mouret-Reynier M, Dubray-Longeras P, Van Praagh I, Passildas J, et al. Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments. Clinical Breast Cancer. Elsevier BV; 2018; 18:e1093-e1102 10.1016/j.clbc.2018.06.010
• Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer Cite
  Li L, Chang B, Jiang X, Fan X, Li Y, Li T, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4878-4
• Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review Cite
  Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. BMJ; 2018;:k3845 10.1136/bmj.k3845
• Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain? Cite
  Leysen L, Adriaenssens N, Nijs J, Pas R, Bilterys T, Vermeir S, et al. Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?. Pain Practice. Wiley; 2018; 19:183-195 10.1111/papr.12732
• Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27 Cite
  Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, et al. Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 110:1003-1008 10.1093/jnci/djy017
• Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure Cite
  Thomas R, Rowell R, Crichton S, Cain H. Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:597-601 10.1007/s10549-018-4943-3
• Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation Cite
  Tanaka M, Itoh S, Takeuchi Y. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. Osteoporosis and Sarcopenia. Elsevier BV; 2018; 4:102-108 10.1016/j.afos.2018.08.002
• Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) Cite
  Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:603-610 10.1007/s10549-018-4946-0
• Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors Cite
  Bouvard B, Chatelais J, Soulié P, Hoppé E, Saulnier P, Capitain O, et al. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. European Journal of Cancer. Elsevier BV; 2018; 101:87-94 10.1016/j.ejca.2018.06.028
• Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors Cite
  Mao H, Bao T, Shen X, Li Q, Seluzicki C, Im E, et al. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors. European Journal of Cancer. Elsevier BV; 2018; 101:47-54 10.1016/j.ejca.2018.06.009
• Abstract 601: Cognitive sequelae of adjuvant endocrine therapy in older women treated for early-stage breast cancer Cite
  Underwood EA, Pritchard KI, Jerzak K, Lebovic G, Elser C, Rochon P, et al. Abstract 601: Cognitive sequelae of adjuvant endocrine therapy in older women treated for early-stage breast cancer. Clinical Research (Excluding Clinical Trials). American Association for Cancer Research; 2018; 10.1158/1538-7445.am2018-601
• Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial Cite
  Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. Elsevier BV; 2018; 114:109-115 10.1016/j.bone.2018.06.007
• Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy Cite
  Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, et al. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. Journal of Cancer Survivorship. Springer Science and Business Media LLC; 2017; 12:268-275 10.1007/s11764-017-0666-4
• Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 Cite
  Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1941-1948 10.1200/jco.2017.76.4258
• Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study Cite
  Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:2061-2069 10.1200/jco.2017.76.3524
• Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Cite
  De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2018; 19:474-485 10.1016/s1470-2045(18)30116-5
• Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors Cite
  Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clinical Breast Cancer. Elsevier BV; 2018; 18:e7-e13 10.1016/j.clbc.2017.11.006
• Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27 Cite
  Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, et al. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical Breast Cancer. Elsevier BV; 2018; 18:78-87 10.1016/j.clbc.2017.10.009
• Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy Cite
  Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, et al. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology. Elsevier BV; 2018; 25:291-300.e3 10.1016/j.chembiol.2017.12.010
• Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis Cite
  Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, et al. Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 168:299-310 10.1007/s10549-017-4627-4
• Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy Cite
  Kwan ML, Yao S, Laurent CA, Roh JM, Quesenberry CP, Kushi LH, et al. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 168:523-530 10.1007/s10549-017-4626-5
• Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 Cite
  Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, O'Shaughnessy J, Parulekar W, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer. Elsevier BV; 2018; 90:19-25 10.1016/j.ejca.2017.11.014
• The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study Cite
  Kristensen B, Ejlertsen B, Jensen M, Mouridsen HT. The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study. Acta Oncologica. Informa UK Limited; 2017; 57:141-145 10.1080/0284186x.2017.1403043
• Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Cite
  Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2018; 19:127-138 10.1016/s1470-2045(17)30715-5
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Cite
  Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:1836-1846 10.1056/nejmoa1701830
• Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis Cite
  Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:31-39 10.1093/jnci/djx141
• Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study Cite
  Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, et al. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:541-547 10.1007/s10549-017-4447-6
• Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) Cite
  Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:40-48 10.1093/jnci/djx134
• Long-Term Follow-Up of the Intergroup Exemestane Study Cite
  Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, et al. Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:2507-2514 10.1200/jco.2016.70.5640
• Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors Cite
  Nyrop KA, Callahan LF, Cleveland RJ, Arbeeva LL, Hackney BS, Muss HB. Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors. The Oncologist. Wiley; 2017; 22:1238-1249 10.1634/theoncologist.2017-0174
• Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy Cite
  Niravath P, Bhat R, Al-Ameri M, AlRawi A, Foreman C, Trivedi MV. Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy. Pharmacology Research & Perspectives. Wiley; 2017; 5:e00330 10.1002/prp2.330
• Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure Cite
  Ramchand SK, Seeman E, Wang X, Ghasem-Zadeh A, Francis PA, Ponnusamy EJ, et al. Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure. Bone. Elsevier BV; 2017; 103:131-135 10.1016/j.bone.2017.06.024
• Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score–matched cohort study Cite
  Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score–matched cohort study. European Journal of Cancer. Elsevier BV; 2017; 82:103-114 10.1016/j.ejca.2017.05.002
• Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients Cite
  He W, Smedby KE, Fang F, Olsson H, Margolin S, Hall P, et al. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 109 10.1093/jnci/djx041
• Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study Cite
  Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, et al. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1179-1188 10.1200/jco.2016.70.3116
• Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line Cite
  Rahideh ST, Keramatipour M, Nourbakhsh M, Koohdani F, Hoseini M, Talebi S, et al. Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line. Biochemistry and Cell Biology. Canadian Science Publishing; 2017; 95:468-473 10.1139/bcb-2016-0206
• Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer Cite
  Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2017; 3:313 10.1001/jamaoncol.2016.3904
• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG Cite
  Hadji P, Aapro MS, Body J, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. Elsevier BV; 2017; 7:1-12 10.1016/j.jbo.2017.03.001
• Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review Cite
  Nyrop KA, Deal AM, Lee JT, Muss HB, Choi SK, Dixon S, et al. Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 162:375-388 10.1007/s10549-017-4106-y
• 27-Hydroxycholesterol induces invasion and migration of breast cancer cells by increasing MMP9 and generating EMT through activation of STAT-3 Cite
  Shen Z, Zhu D, Liu J, Chen J, Liu Y, Hu C, et al. 27-Hydroxycholesterol induces invasion and migration of breast cancer cells by increasing MMP9 and generating EMT through activation of STAT-3. Environmental Toxicology and Pharmacology. Elsevier BV; 2017; 51:1-8 10.1016/j.etap.2017.02.001
• Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer Cite
  Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporosis International. Springer Science and Business Media LLC; 2017; 28:1413-1422 10.1007/s00198-016-3899-6
• Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04) Cite
  Fontein D, Charehbili A, Nortier J, Putter H, Kranenbarg EM, Kroep J, et al. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04). European Journal of Surgical Oncology (EJSO). Elsevier BV; 2017; 43:619-624 10.1016/j.ejso.2016.07.146
• The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors Cite
  Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, et al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors. Obesity. Wiley; 2016; 25:346-351 10.1002/oby.21729
• Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials Cite
  Khosrow-Khavar F, Filion K, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Annals of Oncology. Elsevier BV; 2017; 28:487-496 10.1093/annonc/mdw673
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Cite
  Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. Elsevier BV; 2016; 388:2997-3005 10.1016/s0140-6736(16)32389-3
• Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Cite
  Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:501-512 10.1007/s10549-016-3710-6
• Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy Cite
  Berndt U, Leplow B, Schoenfeld R, Lantzsch T, Grosse R, Thomssen C. Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy. Breast Care. S. Karger AG; 2016; 11:240-246 10.1159/000446901
• Estrogens - the Saviors of Cognitive Function? Cite
  Pfeiler G. Estrogens - the Saviors of Cognitive Function?. Breast Care. S. Karger AG; 2016; 11:238-239 10.1159/000448636
• Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting Cite
  Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, et al. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncology. American Medical Association (AMA); 2017; 3:186 10.1001/jamaoncol.2016.3340
• The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer Cite
  Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ, et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. European Journal of Cancer. Elsevier BV; 2016; 68:11-21 10.1016/j.ejca.2016.08.022
• Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer Cite
  Mori R. Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer. Chemotherapy: Open Access. OMICS Publishing Group; 2016; 05 10.4172/2167-7700.1000210
• Treatment with aromatase inhibitors and markers of cardiovascular disease Cite
  Blondeaux E, Musio D, Bruzzi P, Lambertini M, Gazzola V, Poggio F, et al. Treatment with aromatase inhibitors and markers of cardiovascular disease. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 160:261-267 10.1007/s10549-016-3985-7
• Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis Cite
  Zheng Q, Xia W, Lu Q, Hong R, Qin G, Xu F, et al. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 160:197-209 10.1007/s10549-016-3995-5
• Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells Cite
  Niwa T, Shinagawa Y, Asari Y, Suzuki K, Takanobu J, Gohno T, et al. Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. Elsevier BV; 2017; 165:448-457 10.1016/j.jsbmb.2016.09.008
• Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting Cite
  Seber S, Solmaz D, Yetisyigit T. Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting. OncoTargets and Therapy. Informa UK Limited; 2016; Volume 9:4929-4935 10.2147/ott.s108968
• Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study Cite
  Nestoriuc Y, von Blanckenburg P, Schuricht F, Barsky A, Hadji P, Albert U, et al. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Annals of Oncology. Elsevier BV; 2016; 27:1909-1915 10.1093/annonc/mdw266
• Abstract 3424: Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer Cite
  Engmann NJ, Vachon CM, Scott CG, Jensen MR, Ma L, Brandt KR, et al. Abstract 3424: Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-3424
• Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study Cite
  Altinok A, Yildirim S, Altug T, Sut N, Ober A, Ozsahin E, et al. Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study. The Breast. Elsevier BV; 2016; 28:174-177 10.1016/j.breast.2016.04.003
• Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors Cite
  Chatziralli I, Sergentanis T, Zagouri F, Chrysikos D, Ladas I, Zografos GC, et al. Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors. The Breast Journal. Wiley; 2016; 22:561-563 10.1111/tbj.12633
• Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort Cite
  Persson M, Simonsson M, Markkula A, Rose C, Ingvar C, Jernström H. Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:382-390 10.1038/bjc.2016.174
• Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Cite
  Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. Massachusetts Medical Society; 2016; 375:209-219 10.1056/nejmoa1604700
• Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole Cite
  Arul Vijaya Vani S, Ananthanarayanan P, Kadambari D, Harichandrakumar K, Niranjjan R, Nandeesha H. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole. Clinica Chimica Acta. Elsevier BV; 2016; 459:53-56 10.1016/j.cca.2016.05.020
• Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis Cite
  Eagle I, Benavides E, Eber R, Kolenic G, Jung Y, Van Poznak C, et al. Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis. Journal of Clinical Periodontology. Wiley; 2016; 43:659-667 10.1111/jcpe.12562
• Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials Cite
  Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, et al. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2221-2231 10.1200/jco.2015.64.3171
• Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials Cite
  Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials. The Breast. Elsevier BV; 2016; 26:106-114 10.1016/j.breast.2016.01.006
• Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Cite
  Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen G, et al. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone. Elsevier BV; 2016; 90:123-126 10.1016/j.bone.2016.03.010
• Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions Cite
  Johns C, Seav SM, Dominick SA, Gorman JR, Li H, Natarajan L, et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:415-426 10.1007/s10549-016-3765-4
• Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO Cite
  Bloch W, Baumann F, Zimmer P, Grischke E, Fasching P, Decker T, et al. Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p4-13-07
• Male breast cancer is not congruent with the female disease Cite
  Fentiman IS. Male breast cancer is not congruent with the female disease. Critical Reviews in Oncology/Hematology. Elsevier BV; 2016; 101:119-124 10.1016/j.critrevonc.2016.02.017
• Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety Cite
  Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, et al. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prevention Research. American Association for Cancer Research (AACR); 2016; 9:225-233 10.1158/1940-6207.capr-15-0269
• Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells Cite
  Candelaria NR, Weldon R, Muthusamy S, Nguyen-Vu T, Addanki S, Yoffou P, et al. Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0145061 10.1371/journal.pone.0145061
• A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition Cite
  Zucchini G, Armstrong A, Wardley A, Wilson G, Misra V, Seif M, et al. A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. European Journal of Cancer. Elsevier BV; 2015; 51:2725-2731 10.1016/j.ejca.2015.08.028
• Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial Cite
  Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:139-143 10.1200/jco.2015.63.4972
• Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial Cite
  Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT. Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:3615-3620 10.1200/jco.2015.60.9412
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
  Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
• Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance Cite
  Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Therapeutic Advances in Medical Oncology. SAGE Publications; 2015; 7:291-296 10.1177/1758834015598536
• Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer Cite
  Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. Elsevier BV; 2015; 153:35-44 10.1016/j.jsbmb.2015.07.008
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. Elsevier BV; 2015; 386:1341-1352 10.1016/s0140-6736(15)61074-1
• Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Cite
  Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, et al. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0599-7
• Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study Cite
  Chang C, Chen S, Liu C. Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0130725 10.1371/journal.pone.0130725
• A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors Cite
  Schech A, Yu S, Goloubeva O, McLenithan J, Sabnis G. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. Endocrine-Related Cancer. Bioscientifica; 2015; 22:645-656 10.1530/erc-15-0168
• Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer Cite
  Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, et al. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 152:57-65 10.1007/s10549-015-3423-2
• Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer Cite
  Koopal C, Janssen-Heijnen M, van de Wouw A, van den Bergh J. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer. The Breast. Elsevier BV; 2015; 24:153-158 10.1016/j.breast.2014.12.008
• New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Cite
  HOLE S, PEDERSEN AM, HANSEN SK, LUNDQVIST J, YDE CW, LYKKESFELDT AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Oncology. Spandidos Publications; 2015; 46:1481-1490 10.3892/ijo.2015.2850
• Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial Cite
  Stearns V, Chapman JW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, et al. Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:265-271 10.1200/jco.2014.57.6926
• History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response Cite
  Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, et al. History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 149:505-515 10.1007/s10549-014-3252-8
• Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors Cite
  Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:1104-1111 10.1200/jco.2014.57.1547
• Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis Cite
  Su G, Xiang Y, He G, Jiang C, Li C, Yan Z, et al. Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis. Archives of Medical Research. Elsevier BV; 2014; 45:570-579 10.1016/j.arcmed.2014.10.007
• Modification of Abdominal Fat Distribution After Aromatase Inhibitor Therapy in Breast Cancer Patients Visualized Using 3-D Computed Tomography Volumetry Cite
  Battisti S, Guida FM, Coppa F, Vaccaro DM, Santini D, Tonini G, et al. Modification of Abdominal Fat Distribution After Aromatase Inhibitor Therapy in Breast Cancer Patients Visualized Using 3-D Computed Tomography Volumetry. Clinical Breast Cancer. Elsevier BV; 2014; 14:365-370 10.1016/j.clbc.2014.02.003
• Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer Cite
  Reeder-Hayes KE, Meyer AM, B. Dusetzina S, Liu H, Wheeler SB. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 145:743-751 10.1007/s10549-014-2957-z
• Primary endocrine therapy as a treatment for older women with operable breast cancer – A comparison of randomised controlled trial and cohort study findings Cite
  Morgan J, Reed M, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer – A comparison of randomised controlled trial and cohort study findings. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:676-684 10.1016/j.ejso.2014.02.224
• A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer Cite
  Fenlon D, Addington-Hall JM, O’Callaghan AC, Clough J, Nicholls P, Simmonds P. A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer. Journal of Pain and Symptom Management. Elsevier BV; 2013; 46:523-535 10.1016/j.jpainsymman.2012.10.282
• Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells Cite
  Ismail AM, In LL, Tasyriq M, Syamsir DR, Awang K, Omer Mustafa AH, et al. Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells. Food and Chemical Toxicology. Elsevier BV; 2013; 62:817-824 10.1016/j.fct.2013.10.024
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Cite
  Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1036-1042 10.1093/jnci/djt146
• A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer Cite
  Barron TI, Cahir C, Sharp L, Bennett K. A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2013; 109:1513-1521 10.1038/bjc.2013.518
• Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer Cite
  Hartog H, Boezen H, de Jong M, Schaapveld M, Wesseling J, van der Graaf W. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. The Breast. Elsevier BV; 2013; 22:1155-1160 10.1016/j.breast.2013.07.038
• Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials Cite
  Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 140:233-240 10.1007/s10549-013-2629-4
• Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis Cite
  Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, et al. Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2013; 31:2257-2264 10.1200/jco.2012.45.3068
• Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model Cite
  van Duursen MB, Smeets EE, Rijk JC, Nijmeijer SM, van den Berg M. Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model. Toxicology and Applied Pharmacology. Elsevier BV; 2013; 269:132-140 10.1016/j.taap.2013.03.014
• Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality Cite
  Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. British Journal of Cancer. Springer Science and Business Media LLC; 2013; 108:1515-1524 10.1038/bjc.2013.116
• Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women Cite
  Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. The Breast. Elsevier BV; 2013; 22:121-129 10.1016/j.breast.2013.01.014
• Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment? Cite
  Buwalda B, Schagen SB. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?. Life Sciences. Elsevier BV; 2013; 93:581-588 10.1016/j.lfs.2012.12.012
• Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study Cite
  Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:769-776 10.1007/s10549-012-2294-z
• The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer Cite
  Li F, Chow S, Cheung W, Chan FL, Chen S, Leung LK. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:1112-1116 10.1016/j.jnutbio.2012.08.010
• Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Cite
  Goss P, Ingle J, Martino S, Robert N, Muss H, Livingston R, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. Elsevier BV; 2013; 24:355-361 10.1093/annonc/mds330
• Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients Cite
  Fontein D, Houtsma D, Hille E, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, et al. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. Annals of Oncology. Elsevier BV; 2012; 23:3091-3097 10.1093/annonc/mds204
• Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer Cite
  Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2977-2980 10.1200/jco.2012.42.0273
• Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Cite
  Kim J, Han W, Moon H, Ahn SK, Shin H, You J, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3221
• Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer Cite
  Sandberg MEC, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, et al. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:793-800 10.1007/s10549-012-2096-3
• Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer Cite
  Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:727-734 10.1007/s10549-012-2085-6
• Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation Cite
  Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1062-1067 10.1038/bjc.2012.43
• Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer Cite
  Myrick ME, Schmid SM, Kilic N, Güth U. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer. Acta Oncologica. Informa UK Limited; 2011; 51:247-253 10.3109/0284186x.2011.619567
• Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1. Cite
  Biggar RJ. Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1.. Clinical Cancer Research. American Association for Cancer Research (AACR); 2012; 18:2133-2137 10.1158/1078-0432.ccr-11-1389
• Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group Cite
  Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:722-728 10.1200/jco.2011.36.8993
• Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer Cite
  Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, et al. Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:936-942 10.1200/jco.2011.38.0261
• Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer Cite
  Burstein HJ, Griggs JJ. Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:684-686 10.1200/jco.2011.40.1455
• Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women: A Pilot Study Cite
  Shufelt C, Merz CNB, Yang Y, Kirschner J, Polk D, Stanczyk F, et al. Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women: A Pilot Study. Journal of Women's Health. Mary Ann Liebert Inc; 2012; 21:281-284 10.1089/jwh.2011.3001
• Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole Cite
  Singh S, Cuzick J, Mesher D, Richmond B, Howell A. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:625-629 10.1007/s10549-011-1911-6
• Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) Cite
  Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Breast Cancer. Springer Science and Business Media LLC; 2011; 20:174-180 10.1007/s12282-011-0322-1
• Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle Cite
  Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wöckel A. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:925-931 10.1007/s10549-011-1874-7
• Induced sex reversal using an aromatase inhibitor, Fadrozole, in Atlantic halibut (Hippoglossus hippoglossus L.) Cite
  Babiak J, Babiak I, van Nes S, Harboe T, Haugen T, Norberg B. Induced sex reversal using an aromatase inhibitor, Fadrozole, in Atlantic halibut (Hippoglossus hippoglossus L.). Aquaculture. Elsevier BV; 2012; 324-325:276-280 10.1016/j.aquaculture.2011.11.001
• Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy Cite
  Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. British Journal of Cancer. Springer Science and Business Media LLC; 2011; 105:1825-1829 10.1038/bjc.2011.470
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers. Cite
  Ambros T, Sujoy V, Fernandez CG, Reis I, Wright JL, Jorda M, et al. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:132-132 10.1200/jco.2011.29.27_suppl.132
• Final 5-year results of Z-FAST trial Cite
  Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial. Cancer. Wiley; 2011; 118:1192-1201 10.1002/cncr.26313
• Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Cite
  Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. Elsevier BV; 2012; 23:1474-1481 10.1093/annonc/mdr448
• Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark Cite
  Christiansen P, Bjerre K, Ejlertsen B, Jensen M, Rasmussen BB, Laenkholm A, et al. Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1363-1372 10.1093/jnci/djr299
• Invasive lobular carcinoma: response to neoadjuvant letrozole therapy Cite
  Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 130:871-877 10.1007/s10549-011-1735-4
• Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model Cite
  van Duursen M, Nijmeijer S, de Morree E, de Jong PC, van den Berg M. Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology. Elsevier BV; 2011; 289:67-73 10.1016/j.tox.2011.07.005
• Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? Cite
  Güth U, Myrick ME, Schötzau A, Kilic N, Schmid SM. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:799-807 10.1007/s10549-011-1668-y
• Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer Cite
  Truin W, Voogd AC, Vreugdenhil G, van der Sangen MJ, van Beek MW, Roumen RM. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. The Breast. Elsevier BV; 2011; 20:505-509 10.1016/j.breast.2011.05.005
• An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs). Cite
  Cescon DW, Ennis M, Ganz PA, Beddows S, Stanczyk FZ, Sridhar SS, et al. An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:596-596 10.1200/jco.2011.29.15_suppl.596
• Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. Cite
  Pfeiler G, Königsberg R, Mlineritsch B, Stoger H, Singer CF, Poestlberger S, et al. Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:514-514 10.1200/jco.2011.29.15_suppl.514
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Cite
  Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
• Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland Cite
  Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland. Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 4:329-346 10.1158/1940-6207.capr-10-0381
• Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer Cite
  Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, et al. Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2011; 17:560-568 10.1158/1078-0432.ccr-10-1595
• Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors Cite
  Friedman CF, DeMichele A, Su HI, Feng R, Kapoor S, Desai K, et al. Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors. Journal of Women's Health. Mary Ann Liebert Inc; 2012; 21:456-462 10.1089/jwh.2011.3009
• Abstract B10: Side effects associated with aromatase inhibitor treatment among breast cancer patients Cite
  Gallicchio LM, MacDonald R, Wood B, Rushovich E, Helzlsouer K. Abstract B10: Side effects associated with aromatase inhibitor treatment among breast cancer patients. Behavioral and Social Science. American Association for Cancer Research; 2010; 10.1158/1940-6207.prev-10-b10
• Risk of second breast cancer according to estrogen receptor status and family history Cite
  Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:233-241 10.1007/s10549-010-1137-z
• Sexual Function after Breast Cancer Cite
  Panjari M, Bell RJ, Davis SR. Sexual Function after Breast Cancer. The Journal of Sexual Medicine. Elsevier BV; 2011; 8:294-302 10.1111/j.1743-6109.2010.02034.x
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial Cite
  Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:3411-3415 10.1200/jco.2009.27.2021
• Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors Cite
  Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:205-211 10.1007/s10549-010-0802-6
• Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial Cite
  Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1294-1300 10.1200/jco.2008.21.3553
• The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors Cite
  Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross H. The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors. The Breast. Elsevier BV; 2009; 18:351-355 10.1016/j.breast.2009.09.002
• Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Cite
  Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 120:127-134 10.1007/s10549-009-0692-7
• Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Cite
  Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. Oxford University Press (OUP); 2008; 29:2162-2168 10.1093/carcin/bgn161
• Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer Cite
  Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:111-118 10.1007/s10549-009-0495-x